816 pounds over 16 weeks, often with more dramatic visual change than the scale suggests
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon

This could mean lowering it if cravings resurface or spacing out injections to reduce costs while maintaining progress
If someone has type 2 diabetes and/or obesity, however, their naturally occurring GLP-1 may not be as robust
He is part of the Novo Nordisk Global Expert Panel
Consult with your healthcare provider if you want to stop the medications